Company intelligence / Profile preview

Positivo Biotechnology

Berkeley, California, United Statespositivotecnologia.com.br ↗

Ownership: Private
Development stage: Commercial

Overview

Positivo Biotechnology is developing a novel nonviral, non-integrating DNA gene delivery platform using lipid nanoparticles. Their approach aims to overcome immunogenicity and toxicity issues associated with viral vectors in genetic therapies. The company recently won the 2024 Golden Ticket Award from the Cystic Fibrosis Foundation and Bakar Labs, which provides them with lab space and support to advance their preclinical research in cystic fibrosis. No clinical results have been reported yet as they are still in preclinical development.

Therapeutic areas: Pulmonology
Modalities: DNA gene therapyLipid nanoparticle delivery therapyGene therapy (nonviral, non-integrating)
Industry: Biotech

Partnerships

Cystic Fibrosis Foundation (support/collaboration)

Beyond the preview

Go deeper on Positivo Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Positivo Biotechnology.

Explore the full profile